GeneTx Biotherapeutics LLC was a private biotechnology company that pioneered antisense oligonucleotide (ASO) therapy development for Angelman syndrome, a rare neurogenetic disorder caused by loss of maternal expression of the UBE3A gene. GeneTx was acquired by Ultragenyx Pharmaceutical in 2019 for over $400M, and its lead program GTX-102 is now in late-stage development with a BLA submission expected in Q3-Q4 2026[uxeacq].
GeneTx was founded in 2017 by Dr. Allyson Berent and Dr. Steven Bleyman, parents of a child with Angelman syndrome, along with Dr. Eric Goedken. The company was established with a focus on developing an ASO therapy that could reactivate the silenced paternal UBE3A allele — effectively restoring gene expression without requiring exogenous gene delivery[genetx2022].
Key founding insight: Angelman syndrome results from loss of maternal UBE3A in neurons, but the paternal allele is present and silent. An ASO targeting the UBE3A-antisense transcript (UBE3A-ATS) could unsilence the paternal allele, restoring functional UBE3A protein expression.
Acquisition by Ultragenyx (2019):
Under Ultragenyx, GTX-102 progressed through clinical development:
GTX-102 is an antisense oligonucleotide that targets the UBE3A-antisense transcript (UBE3A-ATS), which is responsible for silencing the paternal UBE3A allele in neurons. By inhibiting UBE3A-ATS, GTX-102 can reactivate expression of the paternal allele, restoring functional UBE3A protein in affected neurons[genetx2024].
Key features:
Angelman syndrome is a rare neurogenetic disorder characterized by:
Caused by loss-of-function of the maternal UBE3A allele in neurons. Affects approximately 1 in 12,000-20,000 live births[angelman2024].
KIK-AS-02 (Phase 1/2, NCT04259281):
Phase 2 study (2024-2025):
GeneTx's ASO approach targets the non-coding UBE3A-antisense transcript (UBE3A-ATS) that naturally silences the paternal allele during neuronal development. This approach:
| Item | Detail |
|---|---|
| Founded | 2017 |
| Acquired by | Ultragenyx Pharmaceutical |
| Acquisition date | 2019 |
| Acquisition value | $400M+ |
| Parent company | Ultragenyx Pharmaceutical (NASDAQ: RARE) |
| Program status | Phase 2, BLA prep |
| Expected BLA submission | Q3-Q4 2026 |
Post-acquisition, GeneTx operates as an integrated Ultragenyx program, with the original founders and team contributing to program development under Ultragenyx leadership[uxeacq].
GTX-102 competes in the Angelman syndrome therapeutic landscape with:
| Competitor | Approach | Stage |
|---|---|---|
| Roche | ASO (UBE3A-ATS targeting) | Discovery |
| Ionis Pharmaceuticals | ASO platform | Discovery |
| Encoded Therapeutics | AAV approach (different mechanism) | Preclinical |
GTX-102 advantages:
Risks: